RxDoctor Payments Data

Eun Ju Yeon, APRN

Adult Health · Livonia, MINPI 1891032009

Payments from drug & device makers

$1,268in general payments, 2019–2025

Across 65 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$455
  • AbbVie$125
  • E.r. Squibb & Sons, L.L.C.$122
  • Bristol Myers Squibb$103
  • Acadia Pharmaceuticals Inc$100
  • Pfizer$75
  • plus $288 from 7 others

What the payments were for

  • Food & beverage$1,268100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,268 in reported general payments places this provider in the 70th percentile of 527 adult health providers in Michigan.

See all adult health providers in Michigan

Medicare billing

Part B allowed, 2024
$155,475
Medicare patients
110
Services billed
2,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide51$38,074
JanuviaSitagliptin Phosphate99$30,032
JardianceEmpagliflozin64$19,692
FarxigaDapagliflozin Propanediol42$12,290
EliquisApixaban36$10,118
Spiriva RespimatTiotropium Bromide17$9,581
Janumet XrSitagliptin Phos/Metformin Hcl28$5,665
Tresiba Flextouch U-200Insulin Degludec17$5,084
XareltoRivaroxaban16$4,287
Divalproex Sodium56$4,134
MyrbetriqMirabegron15$3,966
DapagliflozinDapagliflozin Propanediol13$3,438
Gabapentin137$3,168
Mirtazapine95$3,058
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$3,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$56$12,29042 claims
PfizerEliquis$75$10,11836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 527 adult health providers in Michigan.

Other adult health in Livonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →